Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Annovis Bio (07X) Stock Price & Analysis

4 Followers

07X Stock Chart & Stats

€0.97€0.01(1.25%)
At close: 5:30 PM GMT+1
€1€1.25€1.5Aug 10Aug 31Sep 11Oct 2Oct 7Oct 27
Day’s Range
EUR 0.97 - EUR 0.97
52-Week Range
EUR 0.85 - EUR 4.61
Previous Close
EUR 0.96
Volume
N/A
Average Volume (3M)
28
Market Cap
EUR 46.07M
Enterprise Value
EUR 51.06M
Total Cash (Recent Filing)
EUR 18.73M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
1.17
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.26
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of reported debt reduces refinancing pressure and interest expense, giving Annovis greater flexibility than a similarly loss-making company with leverage. This can preserve strategic options while the company funds clinical development, although it does not remove the need for external capital.

Focused Neurodegenerative Pipeline

Annovis has a clearly defined strategic focus on neurodegenerative diseases, including Alzheimer’s and Parkinson’s, rather than an unfocused set of programs. A concentrated clinical pipeline can support disciplined allocation of research resources and provide a coherent basis for future development milestones.

Improved Reporting Transparency

Correcting the proxy’s audit-fee disclosure improves the accuracy of information available to shareholders and regulators. While the correction does not change financial results, a willingness to address reporting errors supports clearer governance disclosure and can strengthen confidence in future public filings.

Bears Say

No Commercial Revenue And Persistent Losses

Repeated periods without revenue provide no evidence of commercial traction or an established earnings base, while persistent operating and net losses show that spending remains unsupported by top-line generation. This weakens profitability visibility and leaves future value dependent on successful development and commercialization.

Intensifying Cash Burn

Consistently negative operating and free cash flow means the business is not self-funding and must continue financing its operations externally. The sharper TTM deterioration increases the urgency of capital planning, raises dilution risk, and may constrain the pace or breadth of clinical investment.

NYSE Listing And Equity Risk

The NYSE non-compliance notice creates a continuing corporate risk because failure to remediate could lead to suspension or delisting. The issue also reflects weak capitalization, and a stockholders’ deficit can reduce financial resilience while management works to preserve the listing and fund operations.

Annovis Bio News

07X FAQ

What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €0.85 and its highest was €4.61 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is €46.07M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 5 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 14, 2026. The company reported -€0.345 earnings per share for the quarter, beating the consensus estimate of -€0.391 by €0.046.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.26.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,679,058 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€0.345 in its last earnings report, beating expectations of -€0.391. Following the earnings report the stock price went up 0.654%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology